Clinical trials
Atopic Dermatitis (Eczema) clinical trials
Below are recruiting atopic dermatitis (eczema) clinical trials, each written for real people, not researchers. We’re tracking 66 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07022288Recruiting
Study of La Roche-Posay cream for mild facial eczema
This study tests whether a specific soothing moisturizer (La Roche-Posay B5 cream) helps people with mild, stable facial eczema. It is a simple, low-risk trial using a cream you can apply at home.
Shanghai, Shanghai MunicipalityAges 18–65 - NCT07015762RecruitingPhase 1
Testing IBI3002 for moderate-to-severe eczema
This trial tests a new drug called IBI3002 in people with moderate-to-severe atopic dermatitis (eczema) to see if it is safe and tolerable. It may help reduce skin inflammation and itching.
Suzhou, JiangsuAges 18–65 - NCT06998446Recruiting
Sodium in the skin and eczema study
This study looks at sodium levels in the skin of older adults with eczema. It uses an MRI scan to measure sodium and may help us understand how sodium affects eczema severity.
San Francisco, CaliforniaAges 50 years+ - NCT06994520Enrolling by invitationPhase 2
Topical cannabis extract for eczema itch
This study tests a cannabis-based cream on eczema-related itch over 4 weeks. It may help reduce itching if other treatments haven't worked, but requires pausing other skin products during the trial.
Khon Kaen, Changwat Khon KaenAges 25 years+ - NCT06924333Enrolling by invitation
Skin bacteria study in eczema
This study looks at the bacteria and other tiny organisms living on your skin to learn more about skin conditions like eczema. It may help doctors understand why some people get these skin problems.
Lund, Skåne CountyAges 18 years+ - NCT06880276RecruitingPhase 3
Studying QLM3003 ointment for mild or moderate eczema
This trial tests if an ointment called QLM3003 is safe and helps adults with mild to moderate atopic dermatitis (eczema). It may be a new treatment option for people whose eczema affects small areas of skin.
ShenyangAges 18–75 - NCT06855745RecruitingPhase 2
Testing a new gel for mild to moderate eczema
This study tests a new gel called Zabalafin Hydrogel to see if it helps people with mild to moderate atopic dermatitis (eczema). The gel is applied directly to the skin. If you or your child has eczema on the head, neck, trunk, or limbs, this trial may be an option.
Brookvale, New South WalesAges 2 years+ - NCT06775860RecruitingPhase 3
Testing ICP-332 for moderate to severe eczema
This trial tests an oral medication called ICP-332 for adults with moderate to severe eczema (atopic dermatitis) who haven't gotten enough relief from topical creams. It aims to see if the drug can reduce skin inflammation and itching.
Hefei, AnhuiAges 18–75 - NCT06464133Enrolling by invitation
Filaggrin gene study in Latinx patients with eczema
This study looks for gene changes (filaggrin mutations) in Latinx/Hispanic patients with atopic dermatitis (eczema) to better understand how these genes affect the condition. It involves a simple skin test or saliva sample.
Philadelphia, PennsylvaniaAges Any age - NCT06397911RecruitingPhase 2
Testing FB825 for moderate to severe eczema
This trial tests a new injectable medicine called FB825 for people with moderate to severe eczema that hasn't improved enough with standard creams. The study aims to see if FB825 can reduce itching and skin symptoms safely.
Fountain Valley, CaliforniaAges 18–65 - NCT06004986RecruitingPhase 4
Lowering Dupilumab Dose in Controlled Eczema
This study looks at whether people with well-controlled eczema can safely lower their dose of dupilumab (an injected medication). It aims to see if a reduced dose still keeps eczema under control.
Amsterdam, North HollandAges 18 years+ - NCT06096857RecruitingPhase 2
Cardamom and topical bacteria cream for eczema
This study tests whether taking cardamom by mouth and applying a cream made from a harmless bacteria (Roseomonas) can help treat eczema (atopic dermatitis) in people age 2 and older.
Bethesda, MarylandAges 2–100 - NCT05735483Enrolling by invitationPhase 3
Long-term lebrikizumab study for moderate to severe eczema
This Phase 3 trial studies whether lebrikizumab is safe and continues to work over the long term for children and teens with moderate-to-severe atopic dermatitis (eczema). It’s meant for people who already finished a related earlier study and can safely continue.
Birmingham, AlabamaAges 6 months–18 years - NCT05689151Recruiting
Abrocitinib for adult moderate to severe atopic eczema
This study tests how well abrocitinib (a prescription medicine) works for adults with moderate to severe atopic dermatitis (atopic eczema). You may join if you meet the study’s health and consent requirements and your doctor believes abrocitinib is an appropriate option for you.
Amiens, SommeAges 18 years+ - NCT00177268Recruiting
Collecting blood and tissue samples in skin diseases research
This study collects blood, urine, and possibly small tissue samples to learn more about cutaneous T-cell lymphoma (CTCL) and either eczema or atopic dermatitis. It may help researchers better understand these skin conditions and improve future treatments.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT05026554Recruiting
Study of long-term eczema on hands
This trial studies chronic hand eczema (and sometimes related atopic skin disease) to better understand your condition and what may be going on in the skin. You may be asked to follow a study plan for a set period and avoid certain treatments just before joining.
Montreal, QuebecAges 18–65 - NCT01631617RecruitingPhase 2
Atopic dermatitis treatments and how they affect skin
This Phase 2 study tests different treatments for atopic dermatitis (eczema) by looking at changes in skin health. It may help people find safer, more effective ways to control moderate to severe eczema and related skin infections.
Bethesda, MarylandAges 2–50 - NCT05674695Recruiting
Registry study for starting or switching atopic eczema medicines
This study follows people with atopic eczema when they start or switch to a specific medicine that affects the immune system. It helps doctors understand how these treatments work in real life, including for skin symptoms and daily quality of life.
Badalona, BarcelonaAges Any age - NCT07767253RecruitingPhase 3
New injectable medicine for children with moderate to severe eczema
This study tests a new medicine (called 611) given as an injection to children with moderate-to-severe eczema that hasn't improved with creams. The goal is to see if it can reduce itching and clear the rash.
Beijing, Beijing MunicipalityAges 2–11 - NCT07645820Recruiting
Testing a device to detect eczema flares early
This study tests a non-invasive home device called Nevisense Go that may help detect atopic dermatitis (eczema) flares before they become severe. You'll use the device at home, track your symptoms, and visit the clinic a few times to see if it helps predict when flares are coming.
Phoenix, ArizonaAges 12–89 - NCT07239947RecruitingPhase 1
Testing BBT001 for healthy volunteers and people with eczema
This trial tests a new medicine called BBT001, first in healthy people and then in adults with moderate to severe eczema (atopic dermatitis). It aims to see if the drug is safe and how well it works for treating eczema that hasn't improved with topical treatments.
Hefei, AnhuiAges 18–65 - NCT07558668RecruitingPhase 1
Testing SYX-5219 for atopic dermatitis in healthy people and patients
This trial tests a new drug called SYX-5219 to see if it is safe and how the body handles it. Part 1 and 2 use healthy volunteers, while Part 3 tests it in people with moderate to severe atopic dermatitis (eczema). The goal is to understand if this drug might help treat eczema symptoms like itching and skin inflammation.
Arkansas City, ArkansasAges 18–65 - NCT07370909RecruitingPhase 3
Oral LW402 for moderate-to-severe eczema
This trial tests an oral pill called LW402 for people with moderate-to-severe atopic dermatitis (eczema). It aims to see if the drug is safe and effective at reducing skin symptoms.
BeijingAges 18–75 - NCT06723080RecruitingPhase 3
Oral VC005 for moderate to severe eczema
This study tests an investigational oral tablet (VC005) for adults with moderate to severe atopic dermatitis (eczema). It is for people whose eczema has not been controlled well enough with topical treatments.
Nanjing, JiangsuAges 18–75
Hear when a new Atopic Dermatitis (Eczema) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for atopic dermatitis (eczema)?
- Yes. Clin2 currently lists 66 recruiting atopic dermatitis (eczema) studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a atopic dermatitis (eczema) trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a atopic dermatitis (eczema) trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.